8-K: Savara Highlights Positive MOLBREEVI Phase 3 Results

Savara Inc. updated its corporate presentation, detailing positive Phase 3 results for MOLBREEVI in autoimmune PAP and outlining its commercialization strategy.

Summary

• Savara Inc. has updated its corporate presentation, which is now available on its Investor Relations page.
• The presentation focuses on MOLBREEVI (molgramostim inhalation solution), an investigational drug for autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP).
• Autoimmune PAP is a rare, chronic lung disease caused by GM-CSF autoantibodies, leading to surfactant accumulation and impaired oxygen exchange, with no currently approved drugs in the U.S. or Europe.
• The Phase 3 IMPALA-2 trial demonstrated statistically significant positive results for MOLBREEVI compared to placebo.
• The primary endpoint, change from baseline to Week 24 in DLco%, showed a 6.00 difference (MOLBREEVI: 9.8, Placebo: 3.8) with a p-value of 0.0007.
• A key secondary endpoint, change from baseline to Week 48 in DLCO%, showed a 6.90 difference (MOLBREEVI: 11.6, Placebo: 4.7) with a p-value of 0.0008.
• MOLBREEVI also showed statistically significant improvement in SGRQ Total Score at Week 24 (p=0.0072) and nominally significant improvements in SGRQ Activity Score at Week 24 (p=0.0149) and Exercise Capacity (Peak METs) at Week 48 (p=0.0234).
• The drug reduced pulmonary surfactant burden, as indicated by a p-value of 0.0004* (post-hoc) for Ground Glass Opacity Score at Week 24.
• MOLBREEVI was well-tolerated in the IMPALA-2 trial, with a low treatment discontinuation rate of 3% due to drug-related adverse events.
• A Biologics License Application (BLA) for MOLBREEVI was submitted to the FDA in December 2025.
• The estimated U.S. addressable patient population for autoimmune PAP is approximately 5,500, representing a potential market opportunity exceeding $2 billion.
• Savara is well-capitalized with approximately $264.4 million in cash, cash equivalents, and short-term investments as of September 30, 2025, pro forma for an October 2025 equity offering of $140 million (net).

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive clinical trial results for MOLBREEVI, a clear path to regulatory approval with BLA submission, strong market opportunity in an unmet medical need, and a solid financial position. The tone is confident and forward-looking, with minimal explicit negatives.

Positives

• MOLBREEVI achieved statistically significant positive results in the Phase 3 IMPALA-2 trial for autoimmune PAP, demonstrating improvements in lung function (DLco%), quality of life (SGRQ), and exercise capacity.
• The drug was well-tolerated with a low treatment discontinuation rate (3%) in clinical trials, indicating a favorable benefit/risk profile.
• The Biologics License Application (BLA) for MOLBREEVI was submitted to the FDA in December 2025, signaling progress towards regulatory approval.
• MOLBREEVI has received U.S. Orphan Drug Designation (eligible for 7 years exclusivity), Fast Track Designation, and Breakthrough Therapy Designation, which can expedite development and review.
• Upon BLA approval, MOLBREEVI is eligible for 12 years of marketing exclusivity in the U.S., providing a long period of market protection.
• The estimated U.S. total addressable market for autoimmune PAP is approximately 5,500 patients, with a potential market opportunity exceeding $2 billion, indicating significant commercial potential.
• Savara is in a strong financial position, reporting approximately $264.4 million in cash, cash equivalents, and short-term investments (pro forma for an October 2025 equity offering).
• The company holds an exclusive worldwide license to the proprietary eFlow Nebulizer System for MOLBREEVI in autoimmune PAP, ensuring a controlled delivery mechanism.
• There are no FDA-approved therapies for autoimmune PAP, highlighting a substantial unmet medical need that MOLBREEVI aims to address.

Negatives

• MOLBREEVI is an investigational product and has not yet received regulatory approval for sale in any indication.
• The company's ability to fund continued operations relies on the availability of sufficient resources and the timing and ability to raise additional capital as needed.
• While overall positive, some secondary endpoints in the IMPALA-2 trial showed only nominal significance at certain time points, rather than statistical significance.
• One serious adverse event (delusions) in the IMPALA-2 trial was assessed as possibly related to the study drug by the investigator, although it was a single instance.

Risks

• Risks associated with the ability to successfully develop, obtain regulatory approval for, and commercialize MOLBREEVI for autoimmune PAP.
• Risks and uncertainties related to the impact of widespread health concerns and geopolitical conditions on business and operations.
• Risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations.
• The ability to successfully conduct clinical trials for product candidates.
• The availability of sufficient resources and the timing and ability of Savara to raise additional capital as needed to fund continued operations.

Future Outlook

Savara anticipates potential FDA approval for MOLBREEVI, assuming Priority Review, following the BLA submission in December 2025. The company is actively advancing U.S. commercial launch preparations, including multi-channel disease awareness campaigns for healthcare professionals and patients, building critical infrastructure to facilitate access, and hiring key commercial roles starting in Q2 2026. European market development is also underway with planned MAA submissions and identification of centers of excellence.

Management Comments

• "patients with autoimmune PAP are at increased risk of developing pulmonary fibrosis, which in end-stage can be fatal. And consequently, all patients with autoimmune PAP regardless of their severity should receive corrective pharmacotherapy." Dr. Bruce Trapnell, M.D., Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine, Lead Clinical Investigator of the IMPALA-2 trial.

Industry Context

Autoimmune PAP is a rare respiratory disease characterized by a significant unmet medical need, as there are currently no approved drug therapies in the U.S. or Europe. Patients are often subjected to invasive Whole Lung Lavage procedures, which are burdensome and do not address the underlying pathophysiology. MOLBREEVI, if approved, would introduce the first targeted, non-invasive treatment option, potentially transforming patient care. The market for autoimmune PAP is concentrated, allowing for an efficient rare disease commercial model and the potential for orphan drug pricing, aligning with broader industry trends of developing specialized therapies for rare conditions.

Comparison to Industry Standards

• The minimal clinically important difference (MCID) in change in DLCO is 10% in progressive pulmonary fibrosis and 11% in severe COPD. MOLBREEVI in autoimmune PAP showed a ~10% increase from baseline at Week 24 and ~12% increase from baseline at Week 48, indicating clinically meaningful improvements that meet or exceed established MCIDs in other severe lung conditions.

Stakeholder Impact

• **Shareholders**: Potential for significant value creation due to positive clinical trial results, large market opportunity, and long-term exclusivity for MOLBREEVI.
• **Patients**: Access to the first potential approved drug therapy for autoimmune PAP, offering a non-invasive alternative to Whole Lung Lavage and improving lung function, quality of life, and exercise capacity.
• **Healthcare Professionals**: New treatment option for a rare, debilitating disease, supported by a testing program (aPAP ClearPath) to aid diagnosis.
• **Creditors**: Improved financial stability and outlook due to successful capital raise and potential commercialization.

Next Steps

• Potential FDA approval for MOLBREEVI, assuming Priority Review.
• MAA submission in Europe and UK for MOLBREEVI.
• Expand awareness of autoimmune PAP and educate on the importance of early testing through multi-channel campaigns.
• Hire and onboard key commercial roles to expand core commercial activities, starting in Q2 2026.
• Build critical capabilities to facilitate access to MOLBREEVI post-approval, including the MyMOLBREEVI launch support program.
• Ramp up payer stakeholder educational efforts regarding MOLBREEVI's value proposition.

Key Dates

Recommendation

The filing details highly positive Phase 3 clinical trial results for MOLBREEVI, addressing a significant unmet medical need in autoimmune PAP with no currently approved therapies. The BLA submission to the FDA, coupled with multiple regulatory designations (Orphan Drug, Fast Track, Breakthrough Therapy) and 12-year biologic exclusivity, de-risks the regulatory pathway and ensures a durable revenue stream. The estimated U.S. market opportunity exceeds $2 billion, supported by a well-capitalized balance sheet. These factors collectively point to a strong commercial potential and significant upside for investors.

Keywords

Savara, SVRA, MOLBREEVI, molgramostim, autoimmune PAP, pulmonary alveolar proteinosis, rare respiratory disease, orphan drug, FDA approval, BLA submission, clinical trial, IMPALA-2, lung disease, biotechnology, pharmaceutical, drug development, eFlow Nebulizer